Denali Therapeutics (DNLI) Non-Current Assets (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Non-Current Assets data on file, last reported at $243.3 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 38.05% year-over-year to $243.3 million in Q1 2026; TTM through Mar 2026 was $892.0 million, a 56.74% decrease from a year earlier, with the FY2025 full-year figure at $244.2 million, down 52.09% from the prior year.
• Non-Current Assets for Q1 2026 stood at $243.3 million, roughly flat from $244.2 million in the prior quarter.
• Over the last five years, Non-Current Assets for DNLI reached as high as $607.5 million in Q1 2024 and fell as low as $81.7 million in Q2 2023.
• Historically, Non-Current Assets has averaged $270.5 million across 5 years, with a median of $231.5 million in 2025.
• Across the five-year window, Non-Current Assets plunged 82.66% in 2022 and surged 621.67% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $87.9 million in 2022, then grew by 2.11% to $89.8 million in 2023, then jumped by 467.77% to $509.7 million in 2024, then sank by 52.09% to $244.2 million in 2025, then slipped by 0.38% to $243.3 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $243.3 million in Q1 2026, $244.2 million in Q4 2025, and $173.0 million in Q3 2025.